Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01273597 · OUTCOME

Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism

Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands · Source last updated 2013-01-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
6 months prior to start of study through 6 months of treatment

What was measured

If available, data on the use of medication affecting secondary hyperparathyroidism (those who received calcimimetics and calcium supplementation) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.

Analysis population: This outcome measure was not analyzed due to lack of data.

Groups in this outcome

End-stage Kidney Disease With Secondary Hyperparathyroidism

Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
End-stage Kidney Disease With Secondary Hyperparathyroidism0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
If available, data on the use of medication affecting secondary hyperparathyroidism (those who received calcimimetics and calcium supplementation) in the 6 months leading up to paricalcitol treatment and during 6 months of paricalcitol treatment were also collected.
groups
  1. description
    Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
    id
    OG000
    title
    End-stage Kidney Disease With Secondary Hyperparathyroidism
population Description
This outcome measure was not analyzed due to lack of data.
reporting Status
POSTED
time Frame
6 months prior to start of study through 6 months of treatment
title
Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice